208 related articles for article (PubMed ID: 25505249)
1. The unexpected evolution of basic science studies about cyclic nucleotide action into a treatment for erectile dysfunction.
Corbin J
J Biol Chem; 2015 Jan; 290(3):1374-88. PubMed ID: 25505249
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
Francis SH; Morris GZ; Corbin JD
Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
[TBL] [Abstract][Full Text] [Related]
3. PDE5 inhibitors and their applications.
Giovannoni MP; Vergelli C; Graziano A; Dal Piaz V
Curr Med Chem; 2010; 17(24):2564-87. PubMed ID: 20491634
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.
Kim NN
Int J Impot Res; 2003 Oct; 15 Suppl 5():S13-9. PubMed ID: 14551572
[TBL] [Abstract][Full Text] [Related]
5. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
6. Structure -activity relationships of PDE5 inhibitors.
Eros D; Szántai-Kis C; Kiss R; Kéri G; Hegymegi-Barakonyi B; Kövesdi I; Orfi L
Curr Med Chem; 2008; 15(16):1570-85. PubMed ID: 18673225
[TBL] [Abstract][Full Text] [Related]
7. [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology].
Becker AJ; Uckert S; Stief CG
Urologe A; 2008 Dec; 47(12):1582-7. PubMed ID: 18854969
[TBL] [Abstract][Full Text] [Related]
8. Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach.
Ongaro A; Zagotto G; Memo M; Gianoncelli A; Ribaudo G
Nat Prod Res; 2021 May; 35(10):1648-1653. PubMed ID: 31140295
[TBL] [Abstract][Full Text] [Related]
9. Pyrazolopyrimidines in 'all-natural' products for erectile dysfunction treatment: the unreliable quality of dietary supplements.
Schramek N; Wollein U; Eisenreich W
Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2015; 32(2):127-40. PubMed ID: 25517174
[TBL] [Abstract][Full Text] [Related]
10. Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction.
Hudwekar AD; Kotwal P; Dar MI; Balgotra S; Dogra A; Kour J; Chobe SS; Nandi U; Hussain Syed S; Sawant SD
Chem Biodivers; 2023 Apr; 20(4):e202200707. PubMed ID: 36915218
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase inhibitors.
Boswell-Smith V; Spina D; Page CP
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
[TBL] [Abstract][Full Text] [Related]
12. [Chinese herbal drugs for erectile dysfunction through NO-cGMP-PDE5 signaling pathway].
Liao H; Jacob R
Zhonghua Nan Ke Xue; 2012 Mar; 18(3):260-5. PubMed ID: 22474995
[TBL] [Abstract][Full Text] [Related]
13. Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5.
Chau Y; Li FS; Levsh O; Weng JK
PLoS One; 2019; 14(9):e0222803. PubMed ID: 31539416
[TBL] [Abstract][Full Text] [Related]
14. PDE5 inhibitors: in vitro and in vivo pharmacological profile.
Kouvelas D; Goulas A; Papazisis G; Sardeli C; Pourzitaki C
Curr Pharm Des; 2009; 15(30):3464-75. PubMed ID: 19860692
[TBL] [Abstract][Full Text] [Related]
15. Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease.
Gopal A; Sharma T; Calkins JB
J Cardiovasc Pharmacol; 2021 Sep; 78(3):372-376. PubMed ID: 34074904
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Küthe A; Montorsi F; Andersson KE; Stief CG
Curr Opin Investig Drugs; 2002 Oct; 3(10):1489-95. PubMed ID: 12431025
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Corbin JD; Francis SH; Webb DJ
Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol and sildenafil synergistically improve diabetes-associated erectile dysfunction in streptozotocin-induced diabetic rats.
Bai Y; An R
Life Sci; 2015 Aug; 135():43-8. PubMed ID: 26006044
[TBL] [Abstract][Full Text] [Related]
19. Distinct phosphodiesterase 5A-containing compartments allow selective regulation of cGMP-dependent signalling in human arterial smooth muscle cells.
Wilson LS; Guo M; Umana MB; Maurice DH
Cell Signal; 2017 Aug; 36():204-211. PubMed ID: 28506928
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes.
Isidori AM; Cornacchione M; Barbagallo F; Di Grazia A; Barrios F; Fassina L; Monaco L; Giannetta E; Gianfrilli D; Garofalo S; Zhang X; Chen X; Xiang YK; Lenzi A; Pellegrini M; Naro F
Cardiovasc Res; 2015 Jun; 106(3):408-20. PubMed ID: 25852085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
